Relatively Consistent Effects of Canagliflozin (CANA) on Outcomes Regardless of Baseline HbA1c in the CANagliflozin CardioVascular Assessment Study (CANVAS) Program

Relatively Consistent Effects of Canagliflozin (CANA) on Outcomes Regardless of Baseline HbA1c in the CANagliflozin CardioVascular Assessment Study (CANVAS) Program

A prespecified analysis of the CANVAS Program assessed the effects of CANA, an SGLT2 inhibitor, on the risk of cardiovascular (CV), mortality, and renal outcomes in participants with type 2 diabetes mellitus (T2DM) and established CV disease (CVD) or with ≥2 CV risk factors by baseline HbA1c. The pr...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Diabetes (New York, N.Y.) N.Y.), 2018-07, Vol.67 (Supplement_1)
Hauptverfasser: ROSENSTOCK, JULIO, BANTWAL, GANAPATHI, WILDING, JOHN P., DUMAS, RICHARD, GONZALEZ-GALVEZ, GUILLERMO, SLEE, APRIL, VERCRUYSSE, FRANK, MAHAFFEY, KENNETH W., ZEEUW, DICK DE, FULCHER, GREGORY, MATTHEWS, DAVID R.
Format: Artikel
Sprache:eng
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:A prespecified analysis of the CANVAS Program assessed the effects of CANA, an SGLT2 inhibitor, on the risk of cardiovascular (CV), mortality, and renal outcomes in participants with type 2 diabetes mellitus (T2DM) and established CV disease (CVD) or with ≥2 CV risk factors by baseline HbA1c. The primary composite outcome of CV death, nonfatal myocardial infarction, or nonfatal stroke was significantly reduced with CANA vs. placebo (PBO) in the total cohort by 14% (HR 0.86; 95% CI, 0.75, 0.97; P = 0.02). Among CANVAS Program participants, 4,411 (43%) had baseline HbA1c
ISSN:0012-1797
1939-327X
DOI:10.2337/db18-1191-P